What Is a Normal Vitamin D Level in Menopause?

What Is a Normal Vitamin D Level in Menopause?

For most menopausal women, a 25-hydroxyvitamin D [25(OH)D] level between 40–60 ng/mL (100–150 nmol/L) represents a functional optimum — not the often-cited 20 ng/mL that labs flag as 'sufficient.' The main caveat: estrogen loss after menopause accelerates vitamin D metabolism and impairs intestinal calcium absorption, so you may need a higher intake to reach the same serum level you had at 40. Women with darker skin, limited sun exposure, or high body-fat percentage are at greatest risk of falling short.

Why Estrogen Loss Changes Your Vitamin D Needs

Estrogen plays a direct role in vitamin D metabolism that most people — and even some clinicians — overlook. Estrogen upregulates the renal enzyme 1-alpha-hydroxylase, which converts the circulating storage form of vitamin D [25(OH)D] into the biologically active hormone calcitriol [1,25(OH)₂D]. When estrogen drops sharply at menopause, calcitriol production becomes less efficient even when 25(OH)D levels look adequate on a standard panel.

A 2013 analysis published in Menopause found that postmenopausal women had significantly lower active vitamin D metabolite levels compared with premenopausal controls, independent of sun exposure or dietary intake (Cauley et al., Menopause 2013; PMID: 23652031). This partly explains why bone turnover accelerates so rapidly in the first five years after the final menstrual period.

There is also a genomic dimension worth knowing. The vitamin D receptor (VDR) gene contains estrogen response elements, meaning estrogen directly regulates how many VDRs are expressed in target tissues including bone, breast, and brain. After menopause, VDR expression in osteoblasts — the cells that build new bone — declines in parallel with falling estrogen. This is why two women with identical serum 25(OH)D readings can have very different bone remodeling outcomes depending on their menopausal status. The postmenopausal woman is working with both lower calcitriol production AND fewer receptor sites to receive its signal.

Beyond bone, vitamin D receptors are expressed in breast tissue, the brain, immune cells, and vascular smooth muscle. Low 25(OH)D in menopause has been linked to increased risk of low mood in menopause, joint pain, and accelerated muscle loss — all of which share VDR-mediated pathways with calcitriol signaling.

Reference Ranges vs. Optimal Ranges: What the Numbers Mean

Understanding which number to aim for requires distinguishing between three tiers:

The Endocrine Society defines deficiency as < 20 ng/mL but acknowledges that levels up to 50 ng/mL may be required for maximal suppression of parathyroid hormone (PTH) — the hormone that breaks down bone when calcium signaling is disrupted (Holick et al., Journal of Clinical Endocrinology & Metabolism 2011; PMID: 21646368). In postmenopausal women specifically, keeping PTH suppressed is a meaningful therapeutic goal.

A large prospective cohort (n > 36,000) published in JAMA Internal Medicine found that women with 25(OH)D levels above 40 ng/mL had significantly lower all-cause mortality compared with those in the 20–29 ng/mL range, with the strongest protective effect seen for cardiovascular events (Sempos et al., JAMA Intern Med 2013; PMID: 23712304). This doesn't mean higher is always better — levels above 100 ng/mL have been associated with increased risk of falls and hypercalcemia — but it does push the functional target well above the laboratory minimum.

One important exception: women who have had granulomatous diseases such as sarcoidosis, or who have primary hyperparathyroidism, can develop hypercalcemia at vitamin D levels that would be perfectly safe in the general postmenopausal population. These individuals require physician-supervised monitoring before any aggressive repletion.

Symptoms of Low Vitamin D in Menopause

Vitamin D deficiency in menopausal women rarely presents as a single obvious symptom. More commonly, it looks like a cluster of overlapping complaints that get attributed to menopause itself:

• Bone pain and stress fractures — particularly in the hips, lower back, and feet. PTH rises when vitamin D is low, driving osteoclast activity and net bone loss.
• Persistent fatigue and brain fog — VDRs in the brain modulate serotonin synthesis; low calcitriol suppresses this pathway.
• Muscle weakness and poor balance — 1,25(OH)₂D directly regulates muscle protein synthesis; deficiency accelerates the sarcopenia already triggered by estrogen decline. See more on this in our article on muscle loss in menopause.
• Joint pain and stiffness — inflammatory cytokines (IL-6, TNF-α) are upregulated when VDR signaling is inadequate, which can worsen the joint symptoms common after menopause.
• Mood changes, irritability, and depression — low vitamin D status correlates with lower serotonin and dopamine turnover in observational studies.
• Increased infections — vitamin D is essential for innate immune defense, including the production of cathelicidin, a front-line antimicrobial peptide.

A meta-analysis of 37 clinical trials in adults found that vitamin D supplementation reduced the risk of acute respiratory infections by approximately 12%, with a 70% reduction in those who were severely deficient at baseline (Martineau et al., BMJ 2017; PMID: 28202713). For menopausal women whose immune function is already shifting, this is a clinically relevant finding.

The clinical challenge is that these symptoms are nearly identical to core menopause complaints. Fatigue and brain fog accompany falling estradiol; joint pain is so common in perimenopause that it has its own recognition in clinical literature — see is joint pain normal in menopause for context. This overlap means that treating menopause symptoms without checking vitamin D first risks missing a correctable nutritional gap that would otherwise persist regardless of hormonal support.

If you suspect deficiency, the right first step is a 25(OH)D blood test — not supplementation in the dark. Knowing your actual level determines how aggressively you need to correct, and for how long.

How Low Vitamin D Interacts with Other Menopausal Biomarkers

Vitamin D doesn't operate in isolation, and in menopause, it sits at the center of several intersecting hormonal and metabolic pathways.

Vitamin D and thyroid function: VDRs are expressed in thyroid follicular cells, and low 25(OH)D has been associated with higher TPO antibody titers in women with Hashimoto's thyroiditis — a condition that becomes more prevalent around perimenopause. A 2013 intervention study found that 4,000 IU/day of vitamin D3 over four months significantly reduced TPO antibody levels in euthyroid women with elevated antibodies (Mazokopakis et al., Hormones 2015; PMID: 26181193). Monitoring thyroid levels in menopause alongside vitamin D gives a more complete picture of why energy and metabolism may be flagging.

Vitamin D and SHBG: Sex hormone-binding globulin, which regulates bioavailable estrogen and testosterone, is influenced by liver metabolism and systemic inflammation — both of which vitamin D modulates. Understanding what a normal SHBG level looks like in menopause alongside your vitamin D result can clarify whether hormonal or nutritional factors are driving your symptoms.

Vitamin D and calcium-phosphate balance: Without sufficient 25(OH)D, intestinal calcium absorption drops from roughly 30–40% to as low as 10–15%. Combined with the estrogen-driven reduction in calcium retention by the kidneys, this creates a net negative calcium balance that accelerates trabecular bone loss — the kind that leads to vertebral fractures.

Vitamin D and insulin sensitivity: Vitamin D improves insulin receptor sensitivity and glucose uptake in skeletal muscle. A randomized controlled trial in postmenopausal women found that supplementing 1,000 IU/day of vitamin D3 alongside 1,200 mg calcium for 3 years significantly reduced the incidence of type 2 diabetes compared with placebo (Pittas et al., Annals of Internal Medicine 2007; PMID: 17310052). Postmenopausal women already face heightened risk of insulin resistance as visceral adiposity increases; low vitamin D compounds this effect by further impairing skeletal muscle glucose transporter expression.

How to Correct Low Vitamin D: Dosing Evidence

Correcting vitamin D deficiency requires more than a standard multivitamin. Most multivitamins contain 400–1,000 IU of vitamin D3 — amounts that are sufficient for maintenance in replete individuals but inadequate for correction of deficiency.

Correction dosing by baseline level:

The form matters. Vitamin D3 (cholecalciferol) raises serum 25(OH)D approximately 87% more effectively than D2 (ergocalciferol) in head-to-head trials (Tripkovic et al., American Journal of Clinical Nutrition 2012; PMID: 22552031). Always look for D3 on the label.

Timing also matters more than most protocols acknowledge. Daily supplementation consistently outperforms equivalent weekly or monthly bolus dosing for sustained serum level maintenance, even when total IU consumed per month is identical. This is because 25(OH)D has a serum half-life of approximately 2–3 weeks, and large intermittent doses produce transient peaks followed by troughs that don't mirror physiological production from sun exposure.

Co-factors matter equally:

• Vitamin K2 (MK-7) directs calcium deposited under vitamin D's influence into bone and away from arterial walls — without K2, high-dose D3 supplementation theoretically increases soft tissue calcification risk. The MK-7 form of K2 has a plasma half-life of approximately 72 hours versus only 1–2 hours for MK-4, making it the preferred supplemental form. Studies using 90–200 mcg/day of MK-7 have shown measurable improvements in carboxylated osteocalcin, a direct marker of bone matrix mineralization.
• Magnesium: Vitamin D requires magnesium at four enzymatic steps in its activation pathway — including the hepatic 25-hydroxylation step and the renal 1-alpha-hydroxylation step. Roughly 48% of Americans are estimated to consume inadequate dietary magnesium, meaning many people supplement D3 ineffectively because they're magnesium-depleted. In practice, correcting magnesium status before aggressive D3 loading often produces a larger serum 25(OH)D response than simply increasing the D3 dose.
• Omega-3 fatty acids: Vitamin D is fat-soluble; taking it with a meal containing healthy fats increases absorption by up to 32% in pharmacokinetic studies. Beyond absorption, EPA and DHA share anti-inflammatory downstream effects with calcitriol, creating additive benefit for joint and cardiovascular health — two areas particularly affected by menopausal vitamin D decline.

What a practical 12-week repletion protocol looks like:

1. Test baseline 25(OH)D before starting.
2. Choose D3 dose based on baseline level (table above).
3. Take D3 with the largest fat-containing meal of the day.
4. Pair with K2 (MK-7, 90–200 mcg/day) and confirm dietary or supplemental magnesium is adequate.
5. Retest at 12 weeks. If level hasn't risen by at least 10 ng/mL on ≥ 2,000 IU/day, investigate magnesium status and absorption.
6. Once at target (40–60 ng/mL), maintain with 1,000–2,000 IU/day and retest annually.

What This Means for Your Formula

At Ones, blood-work-informed formulation means vitamin D dosing is calibrated to your actual 25(OH)D result — not a one-size-fits-all 1,000 IU. When the AI identifies a gap between your current level and the 40–60 ng/mL functional target, the formula is built to address the full pathway, not just the headline nutrient.

Specifically, Ones formulas relevant to vitamin D optimization include:

• Vitamin D3 + K2 (MK-7): Dosed based on the individual's current 25(OH)D level, with K2 included in the MK-7 form to protect against misdirected calcium deposition — the kind of integrated pairing that isolated D3 supplements skip.
• Magnesium Glycinate (from Ones' Magnesium Complex): Included when low dietary magnesium is likely, since magnesium deficiency is the most common reason D3 supplementation fails to raise serum levels as expected. Magnesium glycinate is favored for its superior bioavailability and reduced laxative effect compared with magnesium oxide.
• Omega-3 (EPA/DHA): Fat-soluble vitamin absorption is directly enhanced by dietary fat co-administration; including Omega-3 in the same formula also addresses the inflammatory pathways that vitamin D and estrogen decline both affect.

For women whose lab panel shows overlapping gaps — low vitamin D alongside thyroid antibodies, low B12, or shifting SHBG — Ones evaluates all findings simultaneously, which is where a single-ingredient approach breaks down. That kind of systems view of menopausal health is harder to replicate with a stack of individually purchased supplements.

Key Takeaways

• The lab 'sufficient' cutoff of 20 ng/mL is too low for most menopausal women — a functional target of 40–60 ng/mL is better supported by outcomes data for bone, mood, immunity, and cardiovascular health.
• Estrogen loss directly impairs vitamin D activation via reduced 1-alpha-hydroxylase activity and lower VDR expression in target tissues, meaning postmenopausal women need higher serum 25(OH)D to achieve the same biological effect.
• Symptoms of deficiency mimic menopause symptoms — fatigue, joint pain, mood changes, and muscle weakness — making blood testing essential before assuming a cause.
• Vitamin D3 (cholecalciferol) raises levels ~87% more effectively than D2, and should always be paired with K2 (MK-7) and taken with a fat-containing meal for optimal absorption.
• Magnesium is a required co-factor at four steps in vitamin D metabolism; deficiency in magnesium can prevent D3 supplementation from raising serum levels even at high doses.
• Correction doses range from 2,000–6,000 IU/day depending on baseline levels — retest at 12 weeks to confirm response and avoid overshoot above 100 ng/mL.

---

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting or changing any supplement regimen.